These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15792917)

  • 1. The ASH/ASCO clinical guidelines on the use of erythropoietin.
    Lichtin A
    Best Pract Res Clin Haematol; 2005; 18(3):433-8. PubMed ID: 15792917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines.
    Djulbegovic B
    Best Pract Res Clin Haematol; 2005; 18(3):455-66. PubMed ID: 15792920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The blue cross blue shield assessment technology review: summary of findings.
    Bennett CL
    Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Erythropoietin: a study of its use in oncohematology].
    Fernández Martín JM; Villa Rubio A; Cameán Fernández M; Borrero Rubio JM; Martínez Díaz C; Díaz Navarro J; Moreno Sánchez FC; Serrano Ruiz FJ
    Farm Hosp; 2004; 28(1):20-8. PubMed ID: 15012175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges.
    Somerfield MR; Einhaus K; Hagerty KL; Brouwers MC; Seidenfeld J; Lyman GH;
    J Clin Oncol; 2008 Aug; 26(24):4022-6. PubMed ID: 18711193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based medicine: can it be applied to stimulation of erythropoiesis for patients with malignancy?
    Rizzo JD
    Best Pract Res Clin Haematol; 2005; 18(3):439-48. PubMed ID: 15792918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia.
    Vaupel P; Dunst J; Engert A; Fandrey J; Feyer P; Freund M; Jelkmann W
    Onkologie; 2005 Apr; 28(4):216-21. PubMed ID: 15840971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin in cancer-related anemia.
    Fenner MH; Ganser A
    Curr Opin Oncol; 2008 Nov; 20(6):685-9. PubMed ID: 18841051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
    Basch EM; Somerfield MR; Beer TM; Carducci MA; Higano CS; Hussain MH; Scher HI;
    J Clin Oncol; 2007 Nov; 25(33):5313-8. PubMed ID: 17925542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical practice guidelines. The Agency for Health Care Policy and Research fosters the development of evidence-based guidelines.
    McCormick KA; Fleming B
    Health Prog; 1992 Dec; 73(10):30-4. PubMed ID: 10122521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.
    Schrag D; Garewal HS; Burstein HJ; Samson DJ; Von Hoff DD; Somerfield MR;
    J Clin Oncol; 2004 Sep; 22(17):3631-8. PubMed ID: 15289488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.
    Rizzo JD; Lichtin AE; Woolf SH; Seidenfeld J; Bennett CL; Cella D; Djulbegovic B; Goode MJ; Jakubowski AA; Lee SJ; Miller CB; Rarick MU; Regan DH; Browman GP; Gordon MS;
    J Clin Oncol; 2002 Oct; 20(19):4083-107. PubMed ID: 12351606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin: a paradigm for the development of practice guidelines.
    Rizzo JD; Seidenfeld J; Piper M; Aronson N; Lichtin A; Littlewood TJ
    Hematology Am Soc Hematol Educ Program; 2001; ():10-30. PubMed ID: 11722976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia: cancer patients who are very likely to benefit often go untreated.
    J Support Oncol; 2003; 1(1):68. PubMed ID: 15352647
    [No Abstract]   [Full Text] [Related]  

  • 17. Erythropoietin-stimulating agents in oncology.
    Savona MR; Silver SM
    Cancer J; 2008; 14(2):75-84. PubMed ID: 18391611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-related anemia and recombinant human erythropoietin--an updated overview.
    Bohlius J; Weingart O; Trelle S; Engert A
    Nat Clin Pract Oncol; 2006 Mar; 3(3):152-64. PubMed ID: 16520805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.